What if the trendiest ingredient in skincare is older than most dermatologists?
Salmon DNA is everywhere. Your TikTok feed. Kim Kardashian's face. Charli XCX's interview quotes. Clinic menus from Seoul to Santa Monica.
The claims are breathtaking: "cellular rejuvenation," "DNA repair," "collagen at the cellular level." Prices range from €15 serums on Amazon to €800 injectable sessions in Gangnam.
And here's what makes this one genuinely interesting: unlike some skincare trends built on vibes and influencer contracts, the biology behind salmon DNA is real. It's been studied for over thirty years. It has legitimate pharmaceutical approvals — in Italy, since 1994. Korean physicians have been injecting it into faces since 2014. There is a mechanism. There is data.
But — and if you've read our editorials on exosomes or collagen supplements, you know what comes next — between that mechanism and the serum on your bathroom shelf lies a significant gap. One that nobody selling you the product has an incentive to explain.
What PDRN actually is (without the PhD)
PDRN stands for polydeoxyribonucleotide. In plain terms: fragments of DNA, chopped into pieces, extracted from salmon sperm cells, and purified until what's left is a clean mixture of nucleotides — the building blocks of DNA.
The extraction uses high temperature to destroy any proteins or peptides that could cause immune reactions, leaving a >95% pure nucleotide mixture. The fragments range from 50 to 1,500 kilodaltons (kDa) in molecular weight, with a peak around 132 kDa.
Why salmon? Not because their DNA is special. Salmon sperm cells are simply an abundant, cheap, reliable source of nucleotides that can be purified at industrial scale. The biology would work with any DNA — salmon just makes economic sense.
Here's how it works in the body. When PDRN is injected into tissue, it does two things. First, it binds to a receptor on cell surfaces — the adenosine A2A receptor — and sets off a chain reaction that tells cells to reduce inflammation, grow new blood vessels, and start proliferating. Second, it feeds nucleotides into the "salvage pathway" — a recycling system cells use to rebuild damaged DNA without making everything from scratch.
This is documented pharmacology, published in Frontiers in Pharmacology (Squadrito et al., 2017, PMID: 28491040), confirmed in laboratory and animal studies, and clinically validated in wound-healing settings — not in topical cosmetic use.
Two words in that description matter more than any others: "injected into." We'll come back to them.
What's in the name — and what's not
When you see "salmon DNA" or "PDRN" on a label, you might assume all these products contain the same thing. They don't.
PDRN and PN (polynucleotides) are often treated as interchangeable in marketing, but they may differ in source, molecular profile, and formulation depending on the product. PDRN is typically extracted from sperm cells and consists of shorter, lighter fragments. PN comes from testes or gonads, tends to have longer chains and higher molecular weight. A 2025 review in Biomolecules (Marques et al., PMID: 39858543) — from Lausanne University Hospital — found that the blurred use of these terms in scientific literature "has led to considerable confusion."
The confusion gets worse at the consumer level. A product labelled "PDRN" might contain pharmaceutical-grade salmon PDRN, trout-derived polynucleotides, plant-derived fragments from ginseng roots, or some unspecified nucleotide extract at an undisclosed concentration. There is no standardised definition of what a cosmetic "PDRN product" must contain.
Two products using the same word on the label may contain fundamentally different molecules. The only thing they reliably share is the marketing.
Where the evidence is strong: wounds, not wrinkles
In wound healing, PDRN has earned its reputation.
The most impressive trial: Squadrito et al. (2014) tested PDRN in diabetic foot ulcers — one of the hardest problems in wound care. PDRN-treated patients nearly doubled the rate of complete healing compared to placebo within eight weeks. Well-designed, properly controlled, and still one of the most compelling pieces of PDRN evidence in any context.
De Caridi et al. (2016, International Wound Journal, PMID: 25639340) found that a gel containing PDRN plus hyaluronic acid achieved complete wound healing in 67% of venous ulcer patients, versus just 22% for hyaluronic acid alone.
In skin grafts, Guizzardi et al. (2002, PMID: 11759182) ran a double-blind, placebo-controlled study showing PDRN significantly improved healing at graft donor sites. For burns, lichen sclerosus, and post-surgical healing, there's a consistent body of smaller studies with plausible mechanisms and real outcomes.
The key fact: all of these studies delivered PDRN by injection or applied it to open wounds — tissue with no intact skin barrier. The drug reached its target cells directly.
What the aesthetic evidence actually shows
Now we move from wound care to beauty, and the landscape changes.
The most rigorous evidence synthesis available is Lampridou et al. (2025, Journal of Cosmetic Dermatology, PMID: 39645667), which searched Embase, Medline, and Cochrane for all primary research on polynucleotides in aesthetic medicine from 2010 to 2024. What they found was mixed: "varying degrees of efficacy and safety, with some studies demonstrating significant improvements in skin elasticity and hydration" — but "others reported limited or no benefits." Worth noting: one co-author is a clinical trainer for a company distributing PN products, and another sits on the same manufacturer's R&D steering board.
A broader 2024 review by Lee et al. (International Journal of Molecular Sciences, PMID: 39125803, PMC11311621) assessed the evidence using Oxford criteria. Most studies rated Level III — observational and case-series quality. The review covered both Korean and Italian products and concluded that "high-quality randomized controlled trials are necessary to establish the effectiveness of polynucleotides."
Here are the specific trials:
Pak et al., 2014 (Journal of Korean Medical Science, PMID: 25473210). Phase III, double-blind, split-face. 72 patients received a PN injectable on one side and hyaluronic acid on the other — three treatments over 12 weeks. No statistically significant difference on primary or secondary endpoints. The animal arm showed improved collagen, but the human trial found equivalence, not superiority. Bottom line: the best-designed trial in the field couldn't distinguish PN from HA.
The 218-subject study. Open-label, no control group, no blinding. It tells us the product is safe and tolerable. It cannot tell us it works better than doing nothing. Bottom line: safety data, not efficacy data.
Lee, 2022 (PMID: 33225778). 27 participants, randomised, double-blind, PN versus HA for periocular rejuvenation. The PN side scored higher at 16 weeks. Bottom line: a promising signal from 27 people at one centre, not proof.
Araco & Araco, 2021 (PMID: 33550367). PN-HPT® (Plinest®) versus placebo for acne scars. 48 patients. Significant improvement. Bottom line: encouraging for scars specifically, but manufacturer-connected and not about general anti-aging.
Araco et al., 2023 (PMID: 35531796). Plinest® for midface rejuvenation. 40 women, open-label, no control. Reported improved elasticity and brightness. Bottom line: promising numbers in search of a control group.
Lim et al., 2024 (PMID: 38322439). PN-HPT® in 28 subjects. No control group.
There is currently no large (n≥200), independent, sham-controlled, randomised trial for any aesthetic PDRN or PN indication. The largest controlled trial couldn't distinguish PN from HA. Most positive results come from small, manufacturer-connected studies without placebo arms.
The evidence is not only thin — it's structurally concentrated around the companies selling the products.
Your face is not a petri dish
You'll sometimes read that PDRN is "clinically proven to stimulate fibroblasts." This is true — in a laboratory dish. When isolated fibroblast cells are placed in a culture medium and PDRN is added directly, the cells proliferate. This is documented and reproducible (Shin et al., 2023, PMID: 37350391).
But between the PDRN in your serum and the fibroblasts in your dermis sits an entire organ — the epidermis — specifically designed to prevent this kind of molecular passage.
Your skin's outermost layer, the stratum corneum, is a stack of 10 to 30 layers of dead, keratinised cells. It blocks pathogens, UV radiation, water loss — and most skincare ingredients above a certain molecular size. The widely used rule of thumb for passive skin penetration is about 500 Daltons. This is a guideline, not an absolute law — exceptions may exist with specific delivery systems — but it's well-established in dermatological science, and no such exception has been demonstrated for PDRN in a controlled human study.
PDRN has a peak molecular weight of approximately 132,000 Daltons. That's 264 times larger than the conventional penetration threshold.
Every clinical study showing benefits delivered PDRN by injection — directly into the dermis, bypassing the barrier entirely. We found no published, peer-reviewed, placebo-controlled clinical trials demonstrating that topically applied PDRN — without microneedling, mesotherapy, or another delivery system — produces measurable anti-aging effects in human skin.
Some formulation scientists describe this as a challenge to be solved through advanced delivery technologies — liposomal encapsulation, nanoparticles, penetration enhancers. These are real areas of research. But making the vehicle smarter doesn't make the molecule smaller. Until someone demonstrates — in a controlled human trial — that a topical formulation can deliver enough PDRN through intact skin to activate dermal fibroblasts, the penetration barrier stands.
If you're applying a PDRN serum with your fingers to intact skin, the observed benefits are more likely attributable to the other well-established moisturising ingredients in the formula — hyaluronic acid, niacinamide, ceramides, panthenol — than to the PDRN itself. If future delivery technologies change this equation, we'll update this assessment. As of today, the evidence isn't there.
How PDRN actually needs to be delivered (and what that means in practice)
This is the part that draws the line between "this ingredient has real biology" and "this product can do something for your skin."
For PDRN to do anything biologically meaningful, it has to physically reach fibroblasts — the cells that produce collagen, elastin, and hyaluronic acid. Fibroblasts live in the dermis, the thick living layer beneath the epidermis. On your face, the epidermis is only about 0.1 to 0.15 mm thick, but those fractions of a millimetre contain the stratum corneum — PDRN's barrier. Below that, the dermis extends 1 to 2 mm, containing the target cells that all the PDRN science is based on.
So what does "getting through" look like in practice?
Mesotherapy injection — what the clinical studies used. A doctor injects PDRN directly into the dermis at 1 to 2 mm depth. The product bypasses the epidermis entirely and lands where fibroblasts live. This is how Placentex® was used since 1994. This is how the Pak Phase III trial delivered the product. This is how wound-healing studies were conducted. When you read "stimulates collagen synthesis" or "activates A2A receptors," injection was the delivery method behind those results.
Products used this way in European clinics include Nucleofill® (Promoitalia, Italy — salmon-derived, the most widely available in the EU), Plinest® and Newest® (Mastelli, Italy — trout-derived, established in France and the UK), and Rejuran® (PharmaResearch, South Korea — salmon-derived, now entering Europe through a distribution deal with VIVACY).
In the United States, no PDRN or PN injectable is FDA-approved for cosmetic use.
Professional microneedling + topical PDRN — the popular clinic combination. A motorised pen device creates thousands of micro-injuries that temporarily open channels through the stratum corneum. PDRN serum is applied during or immediately after needling. In theory, some product diffuses through the channels toward fibroblasts.
Here, the depth of the needles matters enormously.
At 0.25–0.5 mm, you're in the epidermis — through the stratum corneum but not yet in the dermis. There are no fibroblasts and no A2A receptors at this level. Product absorption improves compared to intact skin, so the hydrating ingredients in your serum benefit. But there is currently no convincing evidence that PDRN reaches fibroblasts in meaningful amounts at this depth.
At 1.0 mm, the needles reach the papillary dermis — the upper layer where fibroblasts first appear. This is where PDRN delivery becomes more plausible biologically. But "more plausible" is not "demonstrated." No published controlled study has compared microneedling + topical PDRN versus microneedling + a plain serum to isolate what the PDRN contributed. A 2019 paper was titled, with admirable candour, "Mission impossible: Dermal delivery of growth factors via microneedling" (Dhurat et al., PMID: 30963686).
At 1.5 mm and beyond, the needles reach the dermis proper. According to StatPearls (NBK459344), four microneedling sessions at 1.5 mm produced a 400% increase in collagen and elastin at six months. That's remarkable — but it's from the needling itself, not from any serum applied afterwards. This is firmly professional territory: topical anaesthesia, sterile technique, trained hands.
The uncomfortable pattern: the depths at which PDRN delivery becomes more plausible are also the depths at which home use becomes more risky and less advisable. This isn't a coincidence.
For people who microneedle at home at 1.0 mm or deeper — you deserve honest information rather than silence. At 1.0 mm, some topically applied PDRN may reach the upper dermis through open channels. Whether that amount is enough to produce a clinically meaningful effect is unknown — nobody has measured it. What is known: at this depth, sterile technique matters. Microchannels are open wounds. Infection introduced in non-sterile conditions can cause scarring or hyperpigmentation.
If you're already needling at this depth and want PDRN in your dermis, consider whether a few professional mesotherapy sessions might serve you better. Three or four clinic sessions with a pharmaceutical-grade PN injectable deliver a known quantity to the right tissue layer, in sterile conditions. A serum applied over home microneedling delivers an unknown fraction to an uncertain depth.
The only published study combining microneedling with topical PDRN (Vera & Praharsini, 2025, Aesthetic Medicine) is a two-patient case report for hyperpigmentation — not a controlled trial. That is the entire published evidence base for this combination as of early 2026.
What's available and who's behind it
The aesthetic PDRN/PN market is dominated by three product ecosystems. Understanding who makes what matters — because the published research is closely connected to these same companies.
Nucleofill® (Promoitalia, Milan) uses salmon-derived PN. Currently the most widely distributed PN injectable in European clinics — available in France, Belgium, the UK, and across the EU. CE marked. Administered as mesotherapy, typically three to four sessions spaced three to four weeks apart.
Plinest® and Newest® (Mastelli, Sanremo, Italy) use trout-derived PN with patented PN-HPT™ technology. Mastelli positions Plinest as the original pioneer PN gel. Established across France and the UK. CE marked. Connected to the Araco acne scar RCT (2021), the midface cohort study (2023), and co-authors in the Lampridou systematic review.
Rejuran® (PharmaResearch, South Korea) uses salmon-derived PN. Dominant in Asia since 2014. Entering Europe through a EUR 54.5 million deal with VIVACY covering 22 countries including Belgium. Currently the only PN product approved under the EU Medical Device Regulation (MDR) — a newer framework than the CE marking used by Nucleofill and Plinest. This reflects regulatory pathway and documentation requirements, not proof of superior clinical efficacy. Connected to the Pak Phase III trial and the 218-subject open-label study.
The consumer serum market — the €15–40 products from brands like Medicube, VT Cosmetics, Anua, and Innisfree — is an entirely separate category. These may contain PDRN, PN, plant-derived nucleotides, or unspecified extracts at undisclosed concentrations. There is no shared evidence base with the injectable products. They share a word on the label. That is the extent of the connection.
Who pays for the evidence?
PharmaResearch funds research on its products. Mastelli is connected to the research on Plinest and PN-HPT formulations. Promoitalia's Nucleofill appears in review papers but has fewer dedicated clinical publications. Systematic reviews have co-authors linked to manufacturer distribution networks.
Industry-funded research is the norm in medical devices and aesthetics. But as we showed in our collagen supplements editorial, funding source matters. When researchers filtered collagen supplement studies by who paid for them, the positive effects vanished entirely in independent research.
No equivalent analysis exists for PDRN aesthetics — because there are barely any independent studies to compare against.
Regulation
Europe: Placentex® has been approved by Italy's AIFA since 1994 as a pharmaceutical for wounds and connective tissue. Rejuran® is now the first PN medical device approved under the EU MDR. Nucleofill® and Plinest® are CE marked under earlier frameworks. All three are legally used in European clinics, but the regulatory pathways differ in their requirements.
Topical PDRN products fall under the Cosmetics Regulation (EC 1223/2009). No pre-market efficacy testing required.
South Korea: PN injectables approved by the MFDS since 2014. A 2024 survey (Rho et al., PMID: 38149579) found 64% of Korean dermatologists use PN in their practice.
United States: No PN/PDRN injectable is FDA-approved for cosmetic use. Many clinics offer injections off-label. Topical products are legal as cosmetics.
Belgium: Nucleofill and Plinest are available now. Rejuran is arriving via the VIVACY deal. When choosing a clinic treatment, the practitioner's experience and the honesty of the claims matter more than the brand name.
Safety
PDRN has a genuinely favourable short-term safety profile. The purification process removes proteins that cause immune reactions. Published trials report only minor, transient effects — swelling, bruising, pain, itching. Allergic reactions appear rare; the proteins that trigger seafood allergies aren't present in purified DNA extracts.
There are, however, no long-term safety studies for repeated aesthetic use. Most trials follow patients for 12 to 28 weeks. PDRN promotes cell proliferation, angiogenesis, and growth factor expression — desirable in wound healing. In healthy tissue receiving repeated cosmetic treatments over years, the long-term implications remain unstudied.
In the US, the absence of FDA oversight means product quality varies by supplier.
What this means for you
The biology of PDRN is real and well-characterised. Its pharmaceutical track record in wound healing is legitimate.
The aesthetic evidence is a different story. The largest controlled trial couldn't distinguish PN from hyaluronic acid. Systematic reviews describe inconsistent results. The available clinical literature relies almost entirely on manufacturer-connected research. And the topical serum market has no clinical evidence of its own.
Topical PDRN serum on intact skin: current evidence does not support biological activity. The benefits you experience are more likely from the other proven moisturising ingredients in the formula.
Home microneedling at 0.25–0.5 mm + PDRN serum: the needling improves absorption of hydrating ingredients. Whether PDRN reaches its biological target at this depth is unproven and unlikely based on skin anatomy.
Home microneedling at 1.0 mm+ with PDRN serum: delivery becomes more plausible, but so do the risks. Consider professional mesotherapy for more reliable delivery in safer conditions.
Clinic injectable PN (mesotherapy or skin booster): the delivery method with published evidence behind it. Ask your practitioner: what product are you using, what is its regulatory status, and what controlled trial supports the claim for my specific concern?
We've seen this pattern before. Exosomes: fascinating biology, missing evidence. Collagen supplements: benefits that evaporate without industry funding. LED masks: proven biology, uncertain products.
Salmon DNA fits the same template — with one difference. It has a longer pharmaceutical track record and a more plausible mechanism than most. The foundation is solid. What's missing is the independent, controlled clinical evidence to match the scale of the market claims being made.
Until that evidence arrives, what we have is a promising pharmaceutical ingredient being marketed well beyond what the current science supports. If future research closes this gap, we'll be the first to say so.